NYSE:ELVHealthcare
Elevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?
Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income.
See our latest analysis for Elevance Health.
The share price reaction to Elevance Health's updated guidance has come after a stronger run earlier in the year, with the 90 day share price return up 12.36% and the 1 year total shareholder return at 33.94%. The 3 year total shareholder return...